A synthetic phospho-peptide corresponding to residues surrounding Ser380 and Thr382/383 of human phospho PTEN
Conjugation:
Unconjugated
Alternative Names:
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase, Mutated in multiple advanced cancers 1, MMAC1, Phosphatase and tensin homolog, TEP1
PTEN has been identified as a tumor suppressor gene and has been found to be mutated in a significant number of human cancers, including prostate, brain, and breast cancer. PTEN shares sequence homology with the protein-tyrosine phosphatase (PTPase) family of proteins and negatively regulates the PI3K/Akt pathway. PTEN de-phosphorylates target proteins, and recombinant PTEN has been shown to have phosphoinositide 3-phosphhatase and inositol phosphate 3-phosphatase activity. Studies of primary tumor cells show a loss of PTEN expression after metastasis to the brain, via astrocyte-derived microRNAs. A cluster of phosphorylation sites (S380, T382, T383, and S385) in the C-terminal tail of PTEN drive a conformational change that reduces PTEN activity by inhibiting membrane interactions.
Clonality:
Monoclonal
Clone Designation:
[PTENS380T382383-E4]
Form:
Purified
Application Dilute:
1µg/mL - 0.001µg/mL. It is recommended that the reagent be titrated for optimal performance for each application. See product image legends for additional information.(0.5mg/ml, more than 200 western blots)
* VAT and and shipping costs not included. Errors and price changes excepted
